Research in Brief
This article was originally published in The Gray Sheet
Executive Summary
Neuronetics releases long-term data on NeuroStar TMS therapy for depression. Bayesian methods confirm stenting matches surgery in patients with unprotected left-main disease. More research briefs.
You may also be interested in...
CardioLogical Solutions: Combining Forces To Deliver A Range Of TAVI Accessories
The recently announced merger of two innovative cardiovascular device companies – VasoStitch Inc. and Emboline Inc. – under the name CardioLogical Solutions promises to create a full range of accessory devices to improve the safety and efficacy of transcatheter aortic valve implantation (TAVI) procedures performed by either an interventional cardiologist or a thoracic surgeon.
Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.
Bayesian Gets A Boost With Guidance, But Technique Still Not For Everyone
The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says